Literature DB >> 28633477

Loop diuretics for chronic heart failure: a foe in disguise of a friend?

Chris J Kapelios1, Konstantinos Malliaras1, Elisabeth Kaldara1, Stella Vakrou1, John N Nanas1.   

Abstract

Loop diuretics are recommended for relieving symptoms and signs of congestion in patients with chronic heart failure and are administered to more than 80% of them. However, several of their effects have not systematically been studied. Numerous cohort and four interventional studies have addressed the effect of diuretics on renal function; apart from one prospective study, which showed that diuretics withdrawal is accompanied by increase in some markers of early-detected renal injury, all others converge to the conclusion that diuretics receipt, especially in high doses is associated with increased rates of renal dysfunction. Although a long standing perception has attributed a beneficial effect to diuretics in the setting of chronic heart failure, many cohort studies support that their use, especially in high doses is associated with adverse outcome. Several studies have used propensity scores in order to match diuretic and non-diuretic receiving patients; their results reinforce the notion that diuretics use and high diuretics dose are true risk factors and not disease severity markers, as some have suggested. One small, randomized study has demonstrated that diuretics decrease is feasible and safe and accompanied by a better prognosis. In conclusion, until elegantly designed, randomized trials, powered for clinical endpoints answer the unsettled issues in the field, the use of diuretics in chronic heart failure will remain subject to physicians' preferences and biases and not evidence based. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Furosemide; Hospitalization; Loop diuretics; Mortality; Prognosis; Renal dysfunction

Mesh:

Substances:

Year:  2018        PMID: 28633477     DOI: 10.1093/ehjcvp/pvx020

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


  11 in total

Review 1.  Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?

Authors:  Brian Kerr; Rebabonye B Pharithi; Matthew Barrett; Carmel Halley; Joe Gallagher; Mark Ledwidge; Kenneth McDonald
Journal:  Int J Heart Fail       Date:  2021-02-25

2.  Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction.

Authors:  Stefano Coiro; Nicolas Girerd; John J V McMurray; Bertram Pitt; Karl Swedberg; Dirk J van Veldhuisen; Zohra Lamiral; Patrick Rossignol; Faiez Zannad
Journal:  Clin Res Cardiol       Date:  2021-05-06       Impact factor: 5.460

Review 3.  Hyperkalemia and Renin-Angiotensin-Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction.

Authors:  Giuseppe Mc Rosano; Ilaria Spoletini; Cristiana Vitale; Stefan Agewall
Journal:  Card Fail Rev       Date:  2019-11-04

4.  Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases.

Authors:  Willemien J Kruik-Kollöffel; Job van der Palen; Carine J M Doggen; Marissa C van Maaren; H Joost Kruik; Edith M Heintjes; Kris L L Movig; Gerard C M Linssen
Journal:  PLoS One       Date:  2020-12-22       Impact factor: 3.240

Review 5.  Association of loop diuretics use and dose with outcomes in outpatients with heart failure: a systematic review and meta-analysis of observational studies involving 96,959 patients.

Authors:  Chris J Kapelios; Μaria Bonou; Konstantinos Malliaras; Eleni Athanasiadi; Styliani Vakrou; Marina Skouloudi; Constantina Masoura; John Barbetseas
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

6.  Clinical profile and one-year survival of patients with heart failure with reduced ejection fraction: The largest report from India.

Authors:  Vijay K Chopra; Sanjay Mittal; Manish Bansal; Balbir Singh; Naresh Trehan
Journal:  Indian Heart J       Date:  2019-08-07

7.  Sarcopaenia complicating heart failure.

Authors:  Guilherme Wesley Peixoto da Fonseca; Stephan von Haehling
Journal:  Eur Heart J Suppl       Date:  2019-12-23       Impact factor: 1.803

8.  Drug therapy in elderly heart failure patients.

Authors:  Ewa A Jankowska; Cristiana Vitale; Izabella Uchmanowicz; Michał Tkaczyszyn; Marcin Drozd; Piotr Ponikowski
Journal:  Eur Heart J Suppl       Date:  2019-12-23       Impact factor: 1.803

9.  Renal function, electrolytes, and congestion monitoring in heart failure.

Authors:  Patrick Rossignol; Andrew Js Coats; Ovidiu Chioncel; Ilaria Spoletini; Giuseppe Rosano
Journal:  Eur Heart J Suppl       Date:  2019-12-31       Impact factor: 1.803

10.  Physiological monitoring in the complex multimorbid heart failure patient - Conclusions.

Authors:  Michael Böhm; Andrew J S Coats; Ingrid Kindermann; Ilaria Spoletini; Giuseppe Rosano
Journal:  Eur Heart J Suppl       Date:  2019-12-31       Impact factor: 1.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.